To hardest-to-treat patients, Sanofi's Praluent looks cheap

Payers may already be cooking up ways to reduce the $14,600 yearly price of Sanofi ($SNY) and Regeneron's ($REGN) new PCSK9 drug, Praluent. But to some patients, the drug is a bargain. Those with rare condition heterozygous familial hypercholesterolemia, or FH, can't get their cholesterol levels down to normal with cheaper statins, and insurance companies have set a high bar for covering apheresis--a treatment that can run them $8,000 a month. The question now, The New York Times notes, is whether Praluent's arrival will shed light on the condition and spur doctors to treat it with PCSK9 drugs--and if they do, what it will do to U.S. drug spending. Story | More

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.